Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Low Dose Steroids vs Placebo in Addition to Anti-tuberculosis Treatment (ATT) in Regression of Lymph Node Sizes in Patients With Tuberculous Lymphadenopathy

NCT06236152 is registered in ClinicalTrials.gov with Fahad Javed Awan as lead sponsor.

NCT NCT06236152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06236152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Low Dose Steroids vs Placebo in Addition to Anti-tuberculosis Treatment (ATT) in Regression of Lymph Node Sizes in Patients With Tuberculous Lymphadenopathy
Lead sponsor
Fahad Javed Awan
Phase
Not applicable
Overall status
Completed
Start date
July 1, 2022
Completion date
August 15, 2023
Enrollment
140 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculous lymphadenitis, cervical